Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
Nabriva Therapeutics
About
Nabriva Therapeutics is a biopharmaceutical company focused on the R&D of antibiotics for use in community and hospital infections.
- 101 - 250
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- $75M
- Industries
- Biotechnology,Health Care,Medical
- Founded date
- Jan 1, 2001
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 21, 2018 | Post-IPO Debt | $75M | 1 | — | — | Detail |
| Apr 7, 2015 | Series B | $120M | 2 | — | — | Detail |
| Oct 28, 2009 | Series Unknown | €15M | 2 | — | — | Detail |
| Sep 4, 2007 | Series Unknown | $56M | 1 |
Phase4 Ventures
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Phase4 Ventures
|
Yes | Series Unknown |
Hercules Capital
|
— | Post-IPO Debt |
|
|
— | Series B |
Phase4 Partners
|
— | Series B |
